Next Article in Journal
Do Pentraxins Bind to Fungi in Invasive Human Gastrointestinal Candidiasis?
Next Article in Special Issue
Advances in the Treatment of Mycoses in Pediatric Patients
Previous Article in Journal
Characteristics of Invasive Fungal Infections among HIV Individuals from an Indigenous Origin in Mexico
Previous Article in Special Issue
Fungal Resistance to Echinocandins and the MDR Phenomenon in Candida glabrata
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
J. Fungi 2018, 4(3), 110; https://doi.org/10.3390/jof4030110

Susceptibility Testing of Fungi to Antifungal Drugs

1
Institute of Microbiology, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Università Cattolica del Sacro Cuore, 00168 Rome, Italy
2
Institute of Medical Pathology and Semeiotics, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
*
Author to whom correspondence should be addressed.
Received: 15 July 2018 / Revised: 11 August 2018 / Accepted: 13 August 2018 / Published: 15 September 2018
(This article belongs to the Special Issue Treatments for Fungal Infections)
Full-Text   |   PDF [1234 KB, uploaded 21 September 2018]   |  

Abstract

Susceptibility testing of fungi against antifungal drugs commonly used for therapy is a key component of the care of patients with invasive fungal infections. Antifungal susceptibility testing (AFST) has progressed in recent decades to finally become standardized and available as both Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference methods and in commercial manual/automated phenotypic methods. In clinical practice, the Sensititre YeastOne and Etest methods are widely used for AFST, particularly for sterile site isolates of Candida. Nevertheless, AFST is moving toward new phenotypic methods, such as matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), that are capable of providing rapid, and potentially more actionable, results for the treating clinician. Our objective is to summarize updated data on phenotypic methods for AFST of Candida and Aspergillus species and to assess their significance in view of opposing, but emerging, molecular genotypic methods. View Full-Text
Keywords: antifungal susceptibility; Candida; Aspergillus; CLSI; EUCAST; MALDI-TOF MS antifungal susceptibility; Candida; Aspergillus; CLSI; EUCAST; MALDI-TOF MS
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Sanguinetti, M.; Posteraro, B. Susceptibility Testing of Fungi to Antifungal Drugs. J. Fungi 2018, 4, 110.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Fungi EISSN 2309-608X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top